WAVRE, Belgium — 6 September 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the appointment of Dr Kaweh Mansouri as Chief Medical Officer (CMO).
Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, Clinique de Montchoisi, and an Adjoint Professor at the Department of Ophthalmology, University of Colorado School of Medicine (Denver, USA), he is an expert in the fields of minimally invasive glaucoma surgery (MIGS) and in intraocular pressure (IOP) monitoring.
Prior to joining iSTAR Medical, Dr Mansouri was Chief Medical Officer at Implandata, and served as Chief Medical Officer of Sensimed from 2009-2018, where he pioneered the clinical development of the first smart contact lens for the continuous measurement of IOP.
He has co-authored over 175 peer-reviewed publications and is on the Editorial Board of the Journal of Glaucoma. He is also the Co-Founder and President of the Swiss Glaucoma Research Foundation.
Dr Mansouri graduated from the Medical University of Vienna, before going on to specialize in ophthalmology at the University of Basel, the University of Geneva and the University of Lausanne, Switzerland. He completed his Glaucoma fellowship at the Hamilton Glaucoma Center of the University of California, San Diego, CA, USA. Dr Mansouri also obtained a Masters in Public Health from the University of Geneva.
Michel Vanbrabant, CEO of iSTAR Medical, commented:
We are very pleased to welcome Kaweh, one of the world’s leading specialists in glaucoma and MIGS, as Chief Medical Officer at iSTAR Medical. Kaweh’s expertise in glaucoma and his experience in the treatment of glaucoma patients will be a valuable addition to the leadership team as we continue to develop MINIject® and expand its commercial rollout across Europe.
Prof. Dr Kaweh Mansouri, newly appointed CMO of iSTAR Medical, commented:
MINIject® represents a compelling treatment option for patients currently living with open-angle glaucoma. This innovative MIGS device, with its distinctive STAR® material, allows surgeons to achieve the right balance of meaningful intraocular pressure reduction with favourable safety, sustained over the longer-term. I am excited and look forward to supporting the team in the clinical development of MINIject® both in Europe and in the US through the FDA-approved pivotal STAR-V trial, with a view to increasing access to this transformational device for patients worldwide.
EN
